Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05925036 · ClinicalTrials.gov registry record · Phase 1

Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis

A Phase 1 study of Chronic Pain and Chronic Pancreatitis, sponsored by VA Office of Research and Development.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT05925036 is a Phase 1 study of Chronic Pain and Chronic Pancreatitis that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 40 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05925036, a Phase 1 study of Chronic Pain and Chronic Pancreatitis, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test whether adult stem cells, called mesenchymal stem cells (MSCs) collected from the patient's bone marrow can help reduce pain caused by chronic pancreatitis and improve pancreatic function.

Interventions

  • OTHER Placebo
  • DRUG Mesenchymal stem cells

Study Locations (1)

South Carolina

  • Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-01-01
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT05925036

The ClinicalTrials.gov registry entry for NCT05925036 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05925036 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT05925036 about?

NCT05925036 is a clinical study titled "Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis". The goal of this clinical trial is to test whether adult stem cells, called mesenchymal stem cells (MSCs) collected from the patient's bone marrow can help reduce pain caused by chronic pancreatitis and improve pancreatic function.

What is the current status of trial NCT05925036?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-01-01. Estimated completion is 2027-12-31.

What conditions does trial NCT05925036 study?

This clinical trial studies the following conditions: Chronic Pain, Chronic Pancreatitis.

What interventions are being tested in trial NCT05925036?

The interventions under investigation include: Placebo (OTHER), Mesenchymal stem cells (DRUG).

Who is sponsoring clinical trial NCT05925036?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05925036 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.